Results 161 to 170 of about 25,067 (205)

Targeting NDUFS4 Disrupts Oxidative Phosphorylation and Induces Ferroptosis in Olaparib-Resistant Prostate Cancer. [PDF]

Mol Cancer Ther
Schaaf ZA, Ning S, Leslie AR, Sharifi M, Gao RY, Maine JP, Leslie KD, Shen Y, Lombard AP, Lou W, Li PK, Liu C, Dall'Era M, Gao AC.   +13 more
europepmc   +1 more source

Radiogenomics and the DNA damage response: opportunities for biomarker-guided radiosensitization in pancreatic cancer. [PDF]

Front Oncol
Karam MN, Hajj J, Crane CH, Ramia P, Geara F, Hamadeh N, Scott JG, Grobmyer S, Almond R, O'Reilly EM, Hajj C.   +10 more
europepmc   +1 more source

Plain language summary of results from the DUO-E study: durvalumab given with or without olaparib in patients with advanced endometrial cancer. [PDF]

Future Oncol
Westin SN, Moore K, Chon HS, Lee JY, Thomes Pepin J, Sundborg M, Shai A, de la Garza J, Nishio S, Gold MA, Wang K, McIntyre K, Tillmanns TD, Blank SV, Liu JH, McCollum M, Contreras Mejia F, Nishikawa T, Pennington K, Novak Z, De Melou AC, Sehouli J, Klasa-Mazurkiewicz D, Papadimitriou C, Gil-Martin M, Brasiuniene B, Donnelly C, Liu X, Nieuwenhuysen EV, DUO-E Investigators.   +29 more
europepmc   +1 more source

In Vitro Evaluation of PARP1 Inhibitor Olaparib-Cyanine Dye Conjugate for the Treatment of Glioblastoma. [PDF]

ChemMedChem
Dumo C, Faheem, Choi PJ, Pederson NJ, Liu Y, Dragunow M, Park TI, Diehl KL, Jose J.   +8 more
europepmc   +1 more source

DNA damaging properties of G-quadruplex ligand QN-302 are potentiated by the DNA repair inhibitor Olaparib and mitigated by the molecular helicase PhpC. [PDF]

Genome Biol
Psalmon G, Pipier A, Barbotte M, Hudson RHE, Neidle S, Monchaud D.   +5 more
europepmc   +1 more source

Development and Validation of an SPE-LC-MS Method for the Determination of Epirubicin, Olaparib and Ribociclib in Human Serum. [PDF]

Biomedicines
Popescu MDE, Manda CV, Croitoru O, Calucică DM, Neamțu J, Biță A, Găman AM, Neamțu SD.   +7 more
europepmc   +1 more source

Repression of EGFR by new biguanide 4C potentiated ovarian cancer to PARP inhibitors through down-regulation of BRCA2 and Rad51. [PDF]

Cell Death Dis
Xiao D, Yao J, Yang X, Xie Y, Zhou X, Li D, Peng M, Wang W, Zou H, Yang X.   +9 more
europepmc   +1 more source

Cooperative molecular interaction networks govern PARP1 inhibitor selectivity and binding affinity. [PDF]

PLoS Comput Biol
Feito A, DeMoya-Valenzuela N, Privat C, R Tejedor A, Paniagua-Herranz L, Garaizar A, Ocana A, Espinosa JR.   +7 more
europepmc   +1 more source

Integrative Mendelian Randomization and Multiomics Analysis Identifies CAF-Derived Complement Factor B as a Prognostic Biomarker and Therapeutic Vulnerability in Breast Cancer. [PDF]

Hum Mutat
Xiang H, Ren N, Wang T, Zheng X, Kang Z, Dong Y.   +5 more
europepmc   +1 more source